Company news
Sunshine Biopharma Inc. news in 2024
Sunshine Biopharma Inc.'s news releases, calls and decks from 2024, newest first.
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
December 8, 2024
Sunshine Biopharma Launches a New Generic Prescription Drug
December 3, 2024
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
December 1, 2024
Sunshine Biopharma Launches a New Generic Prescription Drug
November 21, 2024
Business/Financial Results Form 8 K
November 7, 2024
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
November 5, 2024
Sunshine Biopharma launches two new generic prescription drugs
September 27, 2024
Sunshine Biopharma Launches Two New Generic Prescription Drugs
September 25, 2024
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
September 3, 2024
Sunshine Biopharma has launched nine new generic prescription drugs in 2024, now marketing sixty-one generic drugs in Canada
August 27, 2024
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
August 25, 2024
Sunshine Biopharma reports 2024 second quarter results, second qtr revenues up 67%, YTD revenues up 61%
August 20, 2024
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
August 18, 2024
Sunshine Biopharma Announces Reverse Stock Split
August 5, 2024
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
May 20, 2024
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg, a Biosimilar of Neulasta
April 22, 2024
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
April 18, 2024
Sunshine Biopharma Announces Reverse Stock Split
April 11, 2024
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
March 31, 2024
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
February 14, 2024
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
February 12, 2024